Agios Pharmaceuticals is a biopharmaceutical company dedicated to harnessing scientific leadership in cellular metabolism to create life-changing therapies for patients with genetically defined diseases. Their focus is on developing and commercializing novel treatments that address the underlying metabolic dysregulation in these conditions. Agios is known for its commitment to rigorous science, patient advocacy, and a deep understanding of disease biology. Their lead product, PYRUKYND® (mitapivat), is approved for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, with ongoing research into its potential for other rare hematologic disorders and conditions.
The headquarters serves as the central hub for Agios's research and development, corporate operations, strategic planning, commercial activities, and administrative functions.
Modern laboratory and office facilities designed to foster cutting-edge scientific research, collaboration, and innovation, situated within the dynamic Kendall Square/Central Square biotech ecosystem.
Agios cultivates a patient-focused, science-driven, and collaborative work environment. The culture emphasizes innovation, integrity, respect, and a commitment to making a meaningful impact on patients' lives. There is a strong focus on employee growth and development.
Its location in Cambridge, MA, places Agios at the epicenter of the global biotechnology industry, providing unparalleled access to leading academic institutions, research talent, potential partners, and a vibrant scientific community.
Agios Pharmaceuticals' primary operations are centralized at its Cambridge, MA headquarters. From this hub, the company manages its global research programs, clinical trials, regulatory interactions, and commercialization strategies. While they may not maintain numerous physical international offices, their therapies and research initiatives have a global reach, impacting patients and collaborating with researchers and healthcare providers worldwide. Their commercial product, PYRUKYND®, is being developed and commercialized for global markets where approved.
88 Sidney Street
Cambridge
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Agios Pharmaceuticals' leadership includes:
Agios Pharmaceuticals has been backed by several prominent investors over the years, including:
Agios Pharmaceuticals has seen key leadership appointments in the past year, including a new CEO, a new Chief People & Administrative Officer, and a new General Counsel, signaling a refreshed leadership team focused on its strategic priorities in genetically defined diseases.
Discover the tools Agios Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Agios Pharmaceuticals primarily uses the 'first.last' email format. Understanding this common structure can be helpful for professional communication.
first.last@agios.com
Format
jane.doe@agios.com
Example
95%
Success rate
Agios Pharmaceuticals • May 7, 2024
Agios announced its financial results for Q1 2024, highlighting PYRUKYND® net revenue and progress in its clinical development programs for mitapivat in thalassemia and sickle cell disease....more
Agios Pharmaceuticals • April 29, 2024
Agios announced the appointment of David R. Biondo as its new General Counsel and Corporate Secretary, effective May 13, 2024....more
Agios Pharmaceuticals • March 11, 2024
Agios announced the appointment of James K. Dentzer as Chief People and Administrative Officer, effective March 18, 2024....more
Agios Pharmaceuticals • February 15, 2024
Agios provided a business update and reported financial results for Q4 and full year 2023, emphasizing achievements in its PYRUKYND® franchise and pipeline advancements....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Agios Pharmaceuticals, are just a search away.